Kornimate/medical-research-clean huggingface dataset:
pressure release versus thoracic manipulation in rhomboids mps

Conditions: Myofascial Pain Syndrome; Trigger Point Pain, Myofascial

Summary: the purpose of the stud will be to compare the effect of pressure release with thoracic spine manipulation on pain intensity level and pain pressure threshold, thoracic spine rom and physical function onactive rhomboids muscle trigger point in myofascial pain syndrome.

myofascial pain syndrome (mps) is one of the most common chronic disorders causing persistent musculoskeletal pain which is characterized by myofascial trigger points (mtrps) in palpable taut bands of skeletal muscle. in recent years, due to our modern lifestyle people is exposed to postural stresses, inefficient biomechanics, repetitive postural dysfunction, which are some of the causes of myofascial pain syndrome .active rhomboid muscle trigger point are one of the main causes of inter- scapular pain, as the referral pattern of this muscle is on the medial border of the scapula. the aim of the study is to find if there any significant difference between the effect of pressure release and thoracic spine manipulation on pain intensity level, pain pressure threshold ,thoracic spine rom and physical function and symptoms in people with musculoskeletal disorders of the upper limb on active rhomboids muscle trigger point in myofascial pain syndrome. 66 participants will be allocated randomly to three groups ; the participants will be assigned randomly into three groups by simple methods of randomization. control group: will receive conventional physical therapy treatment, experimental group 1: will receive conventional physical therapy treatment in addition to pressure release experimental group 2: will receive conventional physical therapy treatment in addition to thoracic spine manipulation.

Eligibility criteria:
inclusion criteria: participants ages will be from 18 to 30 years participants will be from both genders. participants that have myofascial pain syndrome due to at least one active trigger points in rhomboid muscle (haleema and riaz, 2021). participants have myofascial pain syndrome since more than three months. presence of a palpable taut band in a skeletal muscle exclusion criteria: malignancy. fractures of the thoracic spine. cervical radiculopathy or myelopathy. vascular syndromes such as vertebrobasilar insufficiency. rheumatoid arthritis. neck or upper back surgery. taking anticoagulants. local infection. whiplash injury. open wounds. pregnancy. receiving radiation or chemotherapy. scapular pain due to any degeneration disease. osteoporosis. cardiac pacemaker. any contraindication for thoracic manipulation

Keywords: myofascial pain syndrome pressure release thoracic manipulation active trigger point rhomboids trigger point
a multi-site randomized controlled trial comparing regional and general anesthesia for effects on neurodevelopmental outcome and apnea in infants

Conditions: Inguinal Hernia

Summary: the primary purpose of the gas study is to determine whether different types of anesthesia (regional versus general) given to 720 infants undergoing inguinal hernia repair results in equivalent neurodevelopmental outcomes. the study also aims to describe the incidence of apnea in the post-operative period after both regional and general anesthesia for inguinal hernia repair in infants. this study is important as it will provide the greatest evidence for safety or toxicity of general anesthesia for human infants.

this is a prospective, observer blind, multi-site, randomized, controlled, equivalence trial. the general anesthesia group will receive sevoflurane (intervention drug) for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg per kg) administered via caudal or ilioinguinal nerve block. the airway can be maintained with a face mask, laryngeal mask or endotracheal tube, with or without neuromuscular blocking agents. the regional group will have no sedative agent. the regional blockade may be with spinal alone, spinal block with caudal block, spinal with ilioinguinal block or caudal alone. the maximum dose of 2.5 mg per kg of bupivacaine can be used.

Eligibility criteria:
inclusion criteria: * any infant scheduled for unilateral or bilateral inguinal hernia repair (with or without circumcision) * any infant whose gestational age is 26 weeks or more (ga = 182 days) * any infant whose post-menstrual age is up to 60 weeks (pma = 426 days) exclusion criteria: * any child older than 60 weeks post-menstrual age * any child born less than 26 weeks gestation * any contraindication to general or spinal/caudal anesthesia (for example: neuromuscular disorder or coagulopathy) * pre-operative ventilation immediately prior to surgery * congenital heart disease that has required ongoing pharmacotherapy * known chromosomal abnormality or any other known acquired or congenital abnormalities (apart from prematurity) which are likely to affect development * children where follow-up would be difficult for geographic or social reasons * families where english is not the primary language spoken at home * known neurological injury such as cystic periventricular leukomalacia (pvl), or grade 3 or 4 intra ventricular hemorrhage (ich) (+/- post hemorrhage ventricular dilation) * previous exposure to volatile anesthesia or benzodiazepines as a neonate or in the third trimester in utero.

Keywords: infants scheduled unilateral bilateral repair
clinical trial on the effects and side effects of prooxy in the treatment of acne

Conditions: Acne Vulgaris

Summary: this study was conducted to determine the effects and side effects of prooxy facial spray in the treatment of acne.

a study on the effects and side effects of prooxy facial spray was done. sixty people were selected and approved to participate in this study. pictures of the face (frontal,left side and right side) were taken upon acceptance, during and after treatment at 4,8 and 12 weeks intervals.

Eligibility criteria:
inclusion criteria: * patients with acne on their faces only * patients who are at least 18 years of age * patients who have normal and disease free skin at the dorsal surface of the upper arm. * patients who are willing to follow instructions on both the patch test part one and part two procedures and to follow scheduled visits. exclusion criteria * patients with systemic illnesses(such as but not limited to heart disease, hypertension, diabetes, cancer, liver disease, kidney disease) * patients with very dark skin color, fitzpatrick skin type v-vi, who are prone to post=inflammatory hyperpigmentation. * patients with intake of oral medications including glucocorticoids or any immuno-suppressants or who have undergone ultraviolet phototherapy for the past 2 weeks prior to the patch test. * patients with history of contact dermatitis, dermatographism or anaphylaxis. * patients with history of eczematous and inflammatory dermatitis, seborrheic dermatitis and psoriasis.

Keywords: moderate facial acne acne vulgaris
cost-effectiveness study of beclomethasone versus ciclesonide as controller medications in pediatric asthma

Conditions: Asthma

Summary: the objective was to develop a cost-effectiveness study that compares ciclesonide and beclomethasone in pediatric asthma control.

cost-effectiveness study, of cohorts, observational, analytic, prospective, from health institution perspective. based on published data related to percentage of patients free of crisis for both molecules, it was estimated that the sample size to detect significant differences between the two alternatives was 20 patients per alternative. medical records of 94 patients with diagnosis of uncontrolled asthma were included, aged between 6 and 15 years, 47 received beclomethasone randomly, and 47 received ciclesonide randomly, treatment physician was blind related to this assignation, both cohorts were followed for 6 months, and primary effectiveness variable was defined as number of patients free of crisis with each alternative. cost generating variables were defined as medication use, and hospital stay. decision analysis was based on a decision tree.

Eligibility criteria:
inclusion criteria: * patients with uncontrolled asthma diagnosis * patients with only one controller medication exclusion criteria: * patients without lung infection * patients without antibiotic use
comparison of the change in fat distribution in overweight and obese subjects with type 2 diabetes after insulin treatment

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this clinical trial is to compare the change in trunk fat mass, assessed by double energy x-ray absorptiometry (dexa) after 26 weeks of treatment with insulin detemir or insulin nph (neutral protamine hagedorn) (both combined with insulin aspart at the main meals) in overweight and obese subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes who have been treated with 2 or 3 doses of insulin (one of them must be a premix) for at least 3 months prior to inclusion in trial * glycosylated haemoglobin (hba1c) between 7.0-11.0 % * body mass index (bmi) between 27.5-40 kg/m\^2 exclusion criteria: * treatment with any oral antidiabetic drugs (oads) in the last 6 months except metformin (subjects currently treated with metformin within the interval of 1000 - 2550 mg daily may be included in the trial. the dose should have remained unchanged for a period of 2 months prior to randomisation and should be expected to remain unchanged throughout the trial period) * use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramin, rimonabant) or obesity induced by drug treatment (e.g. corticosteroids, non-steroidal anti-inflammatory drugs (nsaids), tricyclic anti-depressants, atypical anti-psychotics) * previous or planned surgical treatment of obesity * total daily insulin dose higher or equal 2 iu/kg * proliferative retinopathy or maculopathy that has required acute treatment within the last six months * receipt of any investigational drug within 1 month prior to this trial * cardiac disease defined according to new york heart association (nyha) class iii or iv, unstable angina pectoris and/or myocardial infarction within the last 6 months previous to the selection
analysis of the role of t-cell response in patients with atrial fibrillation for clinical application

Conditions: Atrial Fibrillation

Summary: the purpose of this study is 1) to characterize t-cell response in patients with atrial fibrillation, and 2) to analyze the changes of t-cell response after radio-frequency catheter ablation of atrial fibrillation. first, immune-phenotyping and cytokine profiling of t cells from patients with atrial fibrillation will performed. next the difference of t-cell immunity among various type of atrial fibrillation patients will be analyzed. finally the changes of t-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation will be assessed.


Eligibility criteria:
inclusion criteria: * patients who consent with study * patients with age more than19 * patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation exclusion criteria: * patients who do not agree with study inclusion * permanent af refractory to electrical cardioversion * af with rheumatic valvular disease * patients with left atrial diameter greater than 60mm * patients with age less than 19 * patient with malignant tumor and chronic infection disease * patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks
the impact of oxidative stress on erythrocyte biology

Conditions: Sickle Cell Disease Without Crisis

Summary: this study will address if red blood cells transfused to a sickle cell patient from a donor with a glucose-6-phosphate-dehydrogenase (g6pd) enzyme deficiency have a different lifespan as measured by the percentage of red blood cells that survive post-transfusion compared to red blood cells transfused to a sickle cell patient from a donor without a g6pd enzyme deficiency.

this prospective, phase ii, crossover, single-blind, randomized transfusion order study will address if red blood cells from donors with a g6pd enzyme deficiency have a different lifespan once transfused into a patient with sickle cell disease than red blood cells from an otherwise normal donor. results of this critical study will guide future research and donor testing policies to ensure that patients receive the most appropriate units of blood for their condition. each patient randomized to the study will receive 2 blood transfusions, one from a g6pd deficient donor and one from an otherwise normal donor. half the patients (8) will receive g6pd deficient blood first while the other half (8) will receive non-g6pd deficient blood first. patients will have a wash-out period of at least 4 months before receiving the opposite type of blood transfusion. the blood transfusion order will be randomized. there is currently no standard of testing in place to screen blood donations for g6pd enzyme deficiency. it is believed that up to 10% of the antigen-matched donors for patients with sickle cell disease are g6pd deficient, and the lifespan is unknown in the sickle cell population.

Eligibility criteria:
inclusion criteria: * age 18-60 years * has diagnosis of sickle cell disease * steady state (no pain or baseline pain and ≥1 month from any hospital admission) * receiving chronic transfusions (i.e., regular transfusion every 4-8 weeks). exclusion criteria: * history of transfusion reactions not adequately managed by antihistamines * does not have crossmatch compatible red cells * known g6pd deficiency * hepato- or splenomegaly * participation in another therapeutic trial * pregnant or nursing * hiv positive * at investigator discretion for uncontrolled inter-current illness or social situation limiting compliance with study requirements. * inability to speak and/or read english
effect of personalized robotic therapy

Conditions: Stroke

Summary: the primary goal of this project is to test the safeness and clinical effectiveness of a novel exoskeleton for the upper limb (arm light exoskeleton rehab station, alex rs) developed at wearable robotics srl, for the force assistance of stroke patients during robotic-rehabilitation. the secondary study aim is to design and test an automatic personalized robot-based upper limb motor rehabilitation protocol targeting the specific kinematic performance of each patient. finally, the study also aims to define the "neuro-biomechanical state" of the patient and its evolution during the therapy by studying cortical signals and muscular synergies. this information will be used to improve the personalization of the robotic treatment by targeting not only the motor performance but also the cerebral and muscular activity of the patient. the study is longitudinally designed in order to test the safeness and clinical effectiveness of alex rs over time, and to monitor the clinical effectiveness of the automatic personalized robotic therapy from the beginning until the end of the treatment. moreover, in order to estimate the long-term clinical effectiveness of the treatment, the assessment methods proposed in the clinical trial will be repeated one month after the end of the treatment.


Eligibility criteria:
inclusion criteria: * stroke patients * right and left hand dominant * cerebral lesion onset between 2-8 weeks * able to participate in a session of about 30-60 minutes * right-hemiplegic with at least 10° of motion in the treated joints (shoulder and elbow) * age: more than 18 years old exclusion criteria: * subjects with an active implantable device or wearing an active device (e.g., pacemakers, metallic objects in the brain, infusion pumps, etc.) * persistent delirium or disturbed vigilance * moderate or severe language comprehension deficits * skull breach * new stroke lesions during rehabilitation * patients incapable of discernment * subjects with reduced mobility due to previous injuries or abnormalities unrelated with the cerebral accident

Keywords: automatic personalized robotic therapy
a study of zomacton in children with growth hormone deficiency

Conditions: Growth Hormone Deficiency

Summary: this trial is set up to compare zomacton to genotropin for the treatment of growth hormone deficiency in children. the children will be treated for 1 year. half of the patients will be treated with genotropin and half with zomacton. during this time they will be dosed every day by themselves or their parents at home in the evening. there will be 138 patients in the trial from age 3 to age 11. the patients cannot have been treated before with growth hormone and the patients must have a proven growth hormone deficiency, this will be shown by a specific test that will be performed before the trial in the local clinic and once during the trial. during the time of the treatment the patients will come to visit the clinic every 3 months. at these visits their heights will be measured, blood samples will be taken, physical examinations will be performed and questions about their health will be asked. at 2 times in the trial they will have a hand x-ray taken to measure the bone age. at the end of the trial the patients will stop the treatment and continue on one of the marketed products available to treat growth hormone deficiency.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. children aged ≤3yrs old and not above 10 yrs for girls or 11 yrs for boys 3. idiopathic growth hormone deficiency confirmed during the pre-screening period by a standard gh stimulation test (defined as peak level of \<10ng/ml pr lower if so required by the country specific board(s) 4. height sds \<-2 sd of ref value for ca 5. height velocity sdsca ≤ 0 sd of ref value for at lease 6 months prior to pre-screening 6. height recorded for at least 6 months but not more than 18 months of pre-screening 7. the difference between ca-ba≥ 1 8. a positive locally performed gh stimulation test (defined as a peak plasma level of\<9ng/ml or lower if so required by the country specific board(s)) prior to the pre-screening exclusion criteria: 1. ba above 9 yrs for girls and 10 yrs for boys 2. puberty tanner stage \>1 3. weight \<12 kg at screening 4. any prior treatment with gh 5. closed epiphysis 6. any diagnosed or suspected syndrome (e.g. silver -russell, turner's or seckel syndrome) which possibly could affect growth 7. any other diagnosed or suspected endocrine or metabolic disorder 8. any diagnosed or suspected sever chronic disease 9. clinical signs of dysmorphic features, malformations or mental retardations 10. growth failure due to other disorders 11. previous or present use of drugs that could interfere with gh treatment (e.g. steroids) 12. diagnosed malignant disease 13. any abnormal cs lab results that requires further investigation 14. receipt of an investigational drug within the last 28 days preceding screening or longer if considered possible to influence the outcome of the current trial 15. any knowledge of hypersensitivity to somatropin or any of the excipients of zomacton or genotropin
chemotherapy in treating patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not yet known which regimen of chemotherapy is more effective for non-small cell lung cancer. purpose: randomized phase iii trial to compare the effectiveness of two regimens of chemotherapy in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. compare gemcitabine plus vinorelbine vs standard chemotherapy containing cisplatin in terms of the effect on the quality of life of patients with stage iiib or iv non-small cell lung cancer. ii. compare the effect of these regimens on the overall survival of these patients. iii. compare the toxic effects of these regimens in these patients. iv. compare the effect of these regimens on the rate of objective response in these patients. outline: this is a randomized, multicenter study. patients are stratified according to center, stage of disease (iiib vs iv), and performance status (0 vs 1 vs 2). patients are randomized to one of two treatment arms. arm i: patients receive cisplatin iv on day 1 and either gemcitabine iv or vinorelbine iv on days 1 and 8. arm ii: patients receive gemcitabine iv and vinorelbine iv on days 1 and 8. treatment repeats every 21 days for up to 6 courses. quality of life is assessed prior to therapy and before each course of chemotherapy to the fourth course. projected accrual: a total of 500 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically proven non-small cell lung cancer stage iv or stage iiib with supraclavicular lymph node metastases and/or pleural effusion that is not curable with radiotherapy measurable or evaluable disease no cns metastases patient characteristics: age: under 70 performance status: ecog 0-2 life expectancy: not specified hematopoietic: neutrophil count at least 2000/mm3 platelet count at least 100,000/mm3 hemoglobin at least 10 g/dl hepatic: (unless caused by liver metastases) bilirubin no greater than 1.25 times upper limit of normal (uln) sgot or sgpt no greater than 1.25 times uln renal: creatinine no greater than 1.25 times uln other: no prior or concurrent malignancy except basal or squamous cell skin cancer or carcinoma in situ of the cervix prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: not specified radiotherapy: see disease characteristics concurrent palliative radiotherapy allowed surgery: not specified

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
tolerability and pharmacokinetics of lacidipine with and without the co-administration of telmisartan in female and male healthy subjects

Conditions: Healthy

Summary: the objectives of this study are to compare the steady state pharmacokinetics of lacidipine with and without the co-administration of telmisartan and to compare the steady state pharmacokinetics of telmisartan with and without the co-administration of lacidipine


Eligibility criteria:
inclusion criteria: * healthy male and female caucasian subjects as determined by results of screening * written informed consent in accordance with good clinical practice and local legislation given * age \>= 18 and \<= 50 years * broca \>= -20% and \<= + 20% exclusion criteria: * any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ecg) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * surgery of gastrointestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of drugs with a long half-life (\> 24 hours) (\<= 1 month prior to administration or during the trial) * use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial) * participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial) * smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * inability to refrain from smoking on study days * alcohol abuse (\> 60g/day) * drug abuse * blood donation \> 100 ml (\<= 4 weeks prior to administration or during the trial) * any laboratory value outside the reference range of clinical relevance * female only: * no reliable contraception (reliable are: oral contraceptives, 3-month injection, intrauterine devices (iud), sterilization) * pregnancy or breast feeding period